Evidence map›Paper›PMID 40539812›Full record

ArticleAnnals of neurology2025

Decoding the Clinical Features that Associate with Progression, Causes, and Outcomes in Patients with Suspected Rapidly Progressive Dementia.

Yoav D Piura, Nihal Satyadev, Nick Corriveau-Lecavalier, Lindsey A Kuchenbecker, Lauren E Haydu, Michael D Geschwind, Philip W Tipton, Neill R Graff-Radford, Gregory S Day

Abstract read
In one paragraph

Article in Annals of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoav D PiuraDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.ORCID 0000-0003-1004-4560
Nihal SatyadevDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.ORCID 0000-0001-7302-2348
Nick Corriveau-LecavalierDepartment of Psychology and Psychiatry, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-6561-9870
Lindsey A KuchenbeckerDepartment of Neuroscience, Mayo Clinic in Florida, Jacksonville, Florida, USA.ORCID 0000-0002-2987-1040
Lauren E HayduDepartment of Quantitative Health Sciences, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Michael D GeschwindUniversity of California San Francisco, Memory and Aging Center, Weill Neurosciences, Department of Neurology, San Francisco, California, USA.
Philip W TiptonDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.ORCID 0000-0003-4084-2248
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Gregory S DayDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.ORCID 0000-0001-5133-5538

Funding

Bio-RaPID: Biomarkers and Rates of Progression In Dementia.R01AG089380 · NIA · MAYO CLINIC JACKSONVILLE · PI DAY, GREGORY SCOTT · 2024 to 2025
$4.1M
Rapidly Progressive Dementia: Moving Beyond CJDK23AG064029 · NIA · WASHINGTON UNIVERSITY · PI DAY, GREGORY SCOTT · 2019 to 2023
$811k
National Institutes of Health / National Institue on Aging K23AG064029; R01AG089380NIA NIH HHS K23 AG064029NIA NIH HHS R01 AG089380
6 · The paper itself

Abstract

objectiveTo determine the clinical features that identify patients with suspected rapidly progressive dementia (RPD) who will develop RPD.

methodsPatients with suspected RPD were enrolled and followed at Mayo Clinic (Jacksonville, FL; January 2020 to October 2023) and Washington University (Saint Louis, MO; June 2016 to December 2019). Two dementia specialists independently reviewed clinical data and assigned diagnoses. Patients were diagnosed with RPD if they developed dementia within 1 year or incapacitation within 2 years of symptom onset. The associations between clinical features and causes and outcomes were explored via univariate and multivariate comparisons.

resultsOf 248 patients with suspected RPD, 185 (74.6%) met criteria for RPD. Patients with RPD were older (62.6 ± 14.5 vs 55.2 ± 18.1 years; p < 0.001), and more frequently diagnosed with Alzheimer's disease or related dementias (OR 3.13, 95% CI 1.40, 7.31) or Creutzfeldt-Jakob disease (OR 4.67, 95% CI 1.38, 15.75). Visual agnosia (15/183; 8.2%), substantial brain atrophy (27/182; 14.8%), and periodic epileptiform discharges (11/151; 7.3%) were exclusively detected in patients with RPD. After controlling for age, intensive care unit admission (OR 4.77, 95% CI 1.61, 14.12), lack of seizures (OR 2.47, 95% CI 1.15, 5.31), abnormal brain magnetic resonance imaging (OR 2.01, 95% CI 0.997, 4.05), and cerebrospinal fluid white blood cell count ≤5 cells/mm

interpretationSelected clinical features may identify patients with suspected RPD who are likely to continue to decline. Early recognition of these features may improve diagnostic accuracy and inform prognosis. ANN NEUROL 2025;98:764-776.

Indexed as

DementiaDisease ProgressionAgedAged, 80 and overAlzheimer DiseaseCreutzfeldt-Jakob SyndromeFemaleHumansMagnetic Resonance ImagingMaleMiddle Aged

Identifiers

PMID40539812
PMCPMC12283139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.